Oruka Therapeutics (ORKA) Gets a Buy from TD Cowen
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) today. The company’s shares closed ...
Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15%
Key Insights Institutions' substantial holdings in Oruka Therapeutics implies that they have significant influence ...
Promising Potential of Oruka Therapeutics’ ORKA-001 in Psoriasis Treatment
Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) and keeping the price target at ...
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of “Buy” by Analysts
Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have earned a consensus rating of “Buy” from the eight ...
Nasdaq1mon
Oruka Therapeutics reports Q3 EPS ($1.46), consensus (40c)
Chief Executive Officer of Oruka. “We are excited to soon transition to a clinical stage company and show the potential of our programs to raise the bar on what is possible in psoriatic disease.” ...
U.S. News & World Report5mon
9 Short Squeeze Stocks That Could Take Off
The stock jumped in April 2024 after Arca announced a merger with Oruka Therapeutics, a private, clinical-stage biotech company focused on treating chronic skin diseases, including plaque psoriasis.
Investing25d
Oruka Therapeutics gains approval for preferred stock conversion
Oruka Therapeutics, Inc., a company specializing in diagnostic substances, announced the approval of key proposals at its Special Meeting of Stockholders held on November 14, 2024. The ...